RhumbLine Advisers’s Gilead Sciences GILD Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$259M Sell
2,051,819
-184,493
-8% -$24.3M 0.2% 74
2026
Q1
$312M Sell
2,236,312
-34,767
-2% -$4.87M 0.27% 56
2025
Q4
$279M Sell
2,271,079
-56,787
-2% -$6.9M 0.23% 73
2025
Q3
$258M Sell
2,327,866
-15,602
-0.7% -$1.77M 0.21% 79
2025
Q2
$260M Buy
2,343,468
+88,328
+4% +$9.4M 0.22% 69
2025
Q1
$253M Sell
2,255,140
-68,462
-3% -$7.06M 0.24% 69
2024
Q4
$215M Sell
2,323,602
-39,739
-2% -$3.58M 0.19% 83
2024
Q3
$198M Sell
2,363,341
-96,159
-4% -$7.34M 0.18% 98
2024
Q2
$169M Sell
2,459,500
-1,038
-0% -$69.3K 0.16% 108
2024
Q1
$180M Sell
2,460,538
-361,652
-13% -$27.8M 0.17% 103
2023
Q4
$229M Sell
2,822,190
-39,919
-1% -$3.11M 0.24% 73
2023
Q3
$214M Buy
2,862,109
+72,535
+3% +$5.58M 0.25% 67
2023
Q2
$215M Sell
2,789,574
-3,176
-0.1% -$253K 0.24% 72
2023
Q1
$232M Buy
2,792,750
+55,961
+2% +$4.63M 0.29% 63
2022
Q4
$235M Buy
2,736,789
+42,809
+2% +$3.39M 0.32% 59
2022
Q3
$166M Buy
2,693,980
+447,874
+20% +$28.2M 0.25% 75
2022
Q2
$139M Buy
2,246,106
+107,019
+5% +$6.63M 0.2% 89
2022
Q1
$127M Buy
2,139,087
+34,162
+2% +$2.18M 0.16% 108
2021
Q4
$153M Buy
2,104,925
+37,900
+2% +$2.61M 0.19% 95
2021
Q3
$144M Sell
2,067,025
-66,949
-3% -$4.7M 0.2% 92
2021
Q2
$147M Sell
2,133,974
-123,970
-5% -$8.28M 0.19% 93
2021
Q1
$146M Sell
2,257,944
-121,318
-5% -$7.82M 0.2% 96
2020
Q4
$139M Sell
2,379,262
-131,937
-5% -$7.96M 0.19% 96
2020
Q3
$159M Sell
2,511,199
-7,404
-0.3% -$513K 0.25% 75
2020
Q2
$194M Buy
2,518,603
+271,391
+12% +$20.8M 0.32% 57
2020
Q1
$168M Buy
2,247,212
+44,892
+2% +$3.1M 0.35% 54
2019
Q4
$143M Buy
2,202,320
+28,860
+1% +$1.88M 0.24% 76
2019
Q3
$138M Buy
2,173,460
+42,854
+2% +$2.8M 0.25% 74
2019
Q2
$144M Sell
2,130,606
-12,759
-0.6% -$839K 0.27% 65
2019
Q1
$139M Buy
2,143,365
+56,702
+3% +$3.77M 0.27% 68
2018
Q4
$131M Buy
2,086,663
+1,919
+0.1% +$134K 0.28% 68
2018
Q3
$161M Sell
2,084,744
-31,147
-1% -$2.35M 0.31% 61
2018
Q2
$150M Sell
2,115,891
-230,447
-10% -$16.3M 0.3% 62
2018
Q1
$177M Sell
2,346,338
-74,481
-3% -$5.92M 0.37% 50
2017
Q4
$173M Buy
2,420,819
+100,935
+4% +$7.67M 0.35% 49
2017
Q3
$188M Sell
2,319,884
-8,861
-0.4% -$678K 0.41% 42
2017
Q2
$165M Buy
2,328,745
+69,843
+3% +$4.65M 0.38% 44
2017
Q1
$153M Buy
2,258,902
+46,707
+2% +$3.28M 0.36% 45
2016
Q4
$158M Buy
2,212,195
+54,561
+3% +$4.06M 0.4% 42
2016
Q3
$171M Buy
2,157,634
+84,832
+4% +$6.89M 0.47% 39
2016
Q2
$173M Sell
2,072,802
-10,650
-0.5% -$945K 0.51% 38
2016
Q1
$191M Buy
2,083,452
+15,940
+0.8% +$1.44M 0.59% 32
2015
Q4
$209M Sell
2,067,512
-15,694
-0.8% -$1.63M 0.67% 26
2015
Q3
$205M Buy
2,083,206
+23,840
+1% +$2.65M 0.7% 23
2015
Q2
$241M Sell
2,059,366
-439,849
-18% -$48.1M 0.77% 17
2015
Q1
$245M Sell
2,499,215
-56,258
-2% -$5.71M 0.71% 22
2014
Q4
$241M Sell
2,555,473
-51,463
-2% -$5.32M 0.7% 26
2014
Q3
$278M Sell
2,606,936
-65,697
-2% -$6.43M 0.83% 19
2014
Q2
$222M Sell
2,672,633
-88,811
-3% -$6.91M 0.65% 26
2014
Q1
$196M Sell
2,761,444
-6,004
-0.2% -$471K 0.58% 32
2013
Q4
$208M Sell
2,767,448
-115,316
-4% -$8.03M 0.61% 31
2013
Q3
$181M Sell
2,882,764
-71,292
-2% -$4.26M 0.56% 33
2013
Q2
$151M Buy
+2,954,056
New +$154M 0.49% 34

Other funds holding GILD

RhumbLine Advisers's GILD Position: Q2 2026 in Review

RhumbLine Advisers reduced its Gilead Sciences (GILD) stake by 8.2% in Q2 2026, selling an estimated $24.3M and leaving 2,051,819 shares worth $259M. The position accounts for 0.2% of the portfolio, ranked #74.

RhumbLine Advisers first reported a position in GILD in Q2 2013 and has held it in 53 quarters since. The position peaked at $312M in Q1 2026. 2,268 funds tracked by Wall St. Rank hold GILD as of Q2 2026.

  • RhumbLine Advisers held 2,051,819 shares of Gilead Sciences worth $259M as of Q2 2026.
  • RhumbLine Advisers sold 184,493 Gilead Sciences shares in Q2 2026, an estimated $24.3M.
  • Gilead Sciences made up 0.2% of RhumbLine Advisers's portfolio in Q2 2026, its #74 holding.
  • RhumbLine Advisers first reported a position in Gilead Sciences in Q2 2013 and has held it in 53 quarters since.
  • RhumbLine Advisers's Gilead Sciences position peaked at $312M in Q1 2026.
  • 2,268 funds tracked by Wall St. Rank held Gilead Sciences as of Q2 2026.

Based on RhumbLine Advisers's 13F filing for Q2 2026, filed 12 Aug 2026.